Skip to main content

Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC

*April 2024*

The addition of the selective MET TKI savolitinib (Orpathys) to osimertinib (Tagrisso) demonstrated consistent safety and higher clinical activity vs savolitinib plus placebo in patients with EGFR-mutated, MET-amplified advanced non–small cell lung cancer (NSCLC) whose disease had previously progressed on osimertinib, according to findings from a proteogenomic analysis presented at the 2024 AACR Annual Meeting.1

Findings showed that savolitinib plus osimertinib produced an objective response rate (ORR) of 57% (95% CI, 29%-82%) compared with 13% (95% CI, 2%-38%) with savolitinib plus placebo in the overall patient population (n = 30). This was entirely composed of partial responses. The percentage of patients who achieved stable disease (SD) for 5 weeks or longer was 36% with the combination and 31% with placebo plus savolitinib. Disease progression occurred in 7% and 50% of patients in these respective groups.

The median progression-free survival (PFS) with savolitinib plus osimertinib in the overall population was 7.4 months (95% CI, 5.6-not calculable (NC)] compared with 1.6 months (95% CI, 1.3-4.1) with savolitinib plus placebo (HR, 0.07; 95% CI, 0.01-0.25). Importantly, 2 patients who crossed over to the combination arm due to early study termination did not show progression at the data cutoff of December 1, 2022, and were accordingly censored. The median duration of response (DOR) was 30.6 weeks (95% CI, 18.9-NC) in the experimental arm vs NC (95% CI, 12.4-NC) in the control arm. Read more.